Navigation Links
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced clinical trial results related to Halozyme's clinical stage drug, pegylated rHuPH20 (PEGPH20). The results were presented at the 2011 EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer", taking place October 27-29 in Brussels, Belgium.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Today's presentation focused on translational biomarker and pharmacodynamic results from the two Phase 1 dose-finding studies in patients with advanced solid tumors that were unresponsive to prior therapies. Study 101 investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, and Study 102 investigated multiple-dosing of PEGPH20 in combination with dexamethasone.  

Results

The pharmacodynamics of PEGPH20 were first evaluated by measuring the concentration of circulating hyaluronan (HA) catabolites. HA plasma levels increased, in a dose-dependent manner, after PEGPH20 administration. Freeing up of HA by PEGPH20 is consistent with the expected mechanism of PEGPH20.

Tumor imaging from subsets of patients pre- and post-administration of PEGPH20 demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors. Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20. [18F]-fluorodeoxyglucose positron emission tomogra
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
2. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
3. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
4. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
7. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
8. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
9. Halozyme Receives $5.5 Million Payment From Baxter
10. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... 500 companies and professional service industries alike-- typically known for its consummate professionalism-- ... honor a good cause and break from their day jobs. , "Our motto ...
(Date:7/3/2015)... NEW YORK , July 3, 2015  Pomerantz ... filed against Puma Biotechnology, Inc. ("Puma" or the "Company")(NYSE: ... class action, filed in United States District Court, Central ... under 15-cv-00865, is on behalf of a class consisting ... between July 23, 2014 and May 13, 2015 inclusive ...
(Date:7/2/2015)... Md. , July 2, 2015  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... of Spherix Incorporated v. Verizon Services Corp. et ... District Court for the Eastern District of ... on July 1, 2015 interpreting certain key claims in ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... Medivation, Inc. (Nasdaq: MDVN ) ... enrollment in the CONNECTION study, a six-month, confirmatory, pivotal ... patients with mild-to-moderate Alzheimer,s disease. , , ... 598 patients, exceeding the enrollment target of 525 patients. ...
... BioStorage Technologies, Inc., a worldwide provider of ... and cold chain logistics, announced it will participate ... Annual Biorepositories Conference, September 21 to 23, 2009 ... , Biorepositories 2009 is the only U.S.-based ...
... ... everything necessary to build a complete Biotechnology Laboratory, and support US and European power ... Williamstown, ... Stamp™ based Biotechnology laboratory in a box. The CS230000 and CS230001 both are new ...
Cached Biology Technology:Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 2BioStorage Technologies Takes Lead Sponsorship Role of 2nd Annual IIR Biorepositories Conference 3A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box 2
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... The Scripps Research Institute is reporting a discovery that ... everything from the normal processes that govern the everyday ... underlie many diseases, including cancer and septic shock. , ... microRNA and their relationship to the genetic transcripts known ...
... article in Journal of Applied Microbiology investigates how bacteria ... as those of space stations, which feature lowered effects ... modeled reduced gravity" by Paul W. Baker and Laura ... gravity and how for some species, bacteria from the ...
... ability of the brain to recover from such injury as ... that "talk" to one another using the brain chemical acetylcholine, ... Neural repair Group at UCSD have discovered. Their finding in ... by leading to the development of drugs or other treatments ...
Cached Biology News:Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 2Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 4Brain-injury rehabilitation depends on acetylcholine circuitry 2
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Biology Products: